Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab

Pediatric Blood and Cancer

Volumn 53, Issue 3, 2009, Pages 392-396

  Windebank, Kevin ^a,b,e   Walwyn, Tom ^c   Kirk, Richard ^a   Parry, Gareth ^a   Hasan, Asif ^a   Bown, Nick ^d   Wilkins, Bridget ^a,b  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^d NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Burkitt lymphoma; Epstein Barr virus; Immunocompromised host; Immunotherapy; Transplantation; Tumour biology

Indexed keywords

ACICLOVIR; ANTHRACYCLINE; ANTIFUNGAL AGENT; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; IMMUNOGLOBULIN; ITRACONAZOLE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; RAZOXANE; RITUXIMAB; TACROLIMUS; TIOGUANINE; VINCRISTINE;

ABDOMINAL PAIN; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADVANCED CANCER; ANGIOGRAPHY; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ARTICLE; ARTIFICIAL VENTILATION; BACKACHE; BACTEREMIA; BLOOD CELL COUNT; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER REGRESSION; CANCER STAGING; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CASE REPORT; CAUSE OF DEATH; CEREBROSPINAL FLUID; CERVICAL LYMPHADENOPATHY; CHILD; CHROMOSOME TRANSLOCATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CONSTIPATION; CYTOGENETICS; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EPSTEIN BARR VIRUS; FASCICULATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INGUINAL LYMPH NODE; KIDNEY FAILURE; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MALAISE; MALE; MEDICAL RECORD REVIEW; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NEUTROPHIL; NIGHT SWEAT; OUTCOME ASSESSMENT; PNEUMOCYSTIS JIROVECI; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SCHOOL CHILD; SPLENOMEGALY; THROMBOCYTE COUNT; TIC; TUMOR LYSIS SYNDROME; WEIGHT REDUCTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; HEART TRANSPLANTATION; HUMANS; INFANT; MALE; TRANSLOCATION, GENETIC;

EID: 67651216263     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22070     Document Type: Article

References (31)

1. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet 2006;367:233-239. (Pubitemid 43107668)
2. Thorley-Lawson DA. EBV the prototypical human tumor virus-just how bad is it? J Allergy Clin Immunol 2005;116:251-261.
3. Hayashi RJ, Kraus MD, Patel AL, et al. Posttransplant lymphoproliferative disease in children: Correlation of histology to clinical behavior [see comment]. J Pediatr Hematol Oncol 2001;23:14-18.
4. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
5. Maecker B, Jack T, Zimmermann M, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007;25:4902-4908. (Pubitemid 350220420)
6. Tweddle DA, Gennery AR, Reid MM, et al. Posttransplantation B lymphoblastic leukemia with Burkitt-like features. Transplantation 1999;67:1379-1380.
7. Tweddle DA, Windebank KP, Hewson QC, et al. Cyclosporin neurotoxicity after chemotherapy [see comment]. Br Med J 1999;318:1113. (Pubitemid 29192151)
8. Amos Burke GA, Imeson J, Hobson R, et al. Localized non-Hodgkin's lymphoma with B-cell histology: Cure without cyclophosphamide? A report of the United Kingdom Children's Cancer Study Group on studies NHL 8501 and NHL 9001 (1985-1996). Br J Haematol 2003;121:586-5591.
9. Penn I, Hammond W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1:106-112.
10. Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999;67:990-998. (Pubitemid 29200849)
11. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86:3333-3340.
12. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998;92:3137-3147. (Pubitemid 28492320)
13. Gross TG. Treatment of Epstein-Barr virus-associated posttransplant lymphoproliferative disorders [comment]. J Pediatr Hematol Oncol 2001;23:7-9. (Pubitemid 32140370)
14. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005;23:6481-6488.
15. Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for posttransplant lymphoproliferative disorder: The Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005;37:956-957. (Pubitemid 40590757)
16. Suryanarayan K, Natkunam Y, Berry G, et al. Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation. J Pediatr Hematol Oncol 2001;23:452-455. (Pubitemid 33031775)
17. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000;11:113-116. (Pubitemid 30111878)
18. Oertel SHK, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-2906. (Pubitemid 43923950)
19. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006;107:3053-3057.
20. Messahel B, Taj MM, Hobson R, et al. Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: A United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review. Leuk Lymphoma 2006;47:2584-2589. (Pubitemid 44932648)
21. Trappe RU, Choquet S, Reinke P, et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: The role of single-agent rituximab. Transplantation 2007;84:1708-1712.
22. Orjuela M, Gross TG, Cheung Y-K, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9:3945S-3952S. (Pubitemid 37169201)
23. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007;86:599-607. (Pubitemid 47018478)
24. Choquet S, Trappe R, Leblond V, et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007;92:273-274. (Pubitemid 46852438)
25. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-1555.
26. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007;110:1123-1131. (Pubitemid 47281407)
27. Gallego-Melcon S, Sanchez de Toledo J, Martinez V, et al. Non-Hodgkin's lymphoma after liver transplantation: Response to chemotherapy. Med Pediatr Oncol 1996;27:156-159. (Pubitemid 26282095)
28. Gong JZ, Stenzel TT, Bennett ER, et al. Burkitt lymphoma arising in organ transplant recipients: A clinicopathologic study of five cases. Am J Surg Pathol 2003;27:818-827. (Pubitemid 36617520)
29. Patte C, Michon J, Frappaz D, et al. Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: Experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol 1994;7:339-348. (Pubitemid 24229753)
30. Friedberg J. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology 2005; 1:329-334.
31. Freim Wahl SG, Folvik MR, Torp SH. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: Case report and review of the literature. Clin Neuropathol 2007;26: 68-73.